SPOTLIGHT -
Dr. Hill and Dr. Sauter Consider CAR T-Cell Therapy in Second-Line Setting for DLBCL
Craig Sauter, MD, and Brian T. Hill, MD, PhD, consider CAR T-cell therapy in the second-line setting for patients with diffuse large B-cell lymphoma.
Read More
Cleveland Clinic Experts Assess Strategies to Accelerate CAR T-Cell Production
Craig Sauter, MD, and Brian T. Hill, MD, PhD, discuss recent data showing that the CAR T-cell production can be shortened.
Dr. Hill and Dr. Sauter Discuss the Future of CAR T-Cell Products Agents in Lymphoma
Craig Sauter, MD, and Brian T. Hill, MD, PhD, discuss potential directions for CAR T-cell therapy in lymphomas.
Cleveland Clinic Experts Discuss the Potential for Allogeneic CAR T-Cell Agents
Brian T. Hill, MD, PhD, and Craig Sauter, MD, discuss the promise of allogeneic CAR T-cell products.
Dr. Hill and Dr. Sauter Address Financial Toxicity in CAR T-Cell Therapy
Craig Sauter, MD, and Brian T. Hill, MD, PhD, address the issue of financial toxicity in CAR T-cell therapy.
Dr. Hill on the Safety Profiles of BTK Inhibitors in MCL
Brian T. Hill, MD, PhD, discusses the safety profiles of BTK inhibitors in mantle cell lymphoma.
Novel Therapies: R2-GDP-GOTEL and Smart Start
Novel Treatment Combinations for R/R DLBCL
Relapsed/Refractory DLBCL: Unmet Needs
Emerging Treatments for Relapsed/Refractory DLBCL
SADAL Trial Regimen FDA Approval
SADAL Trial Overview
CAR T-Cell Therapy Clinical Trials
CAR T-Cell Therapy Response Rates
CAR T Cell Therapy in Relapsed/Refractory DLBCL
Relapsed/Refractory DLBCL Treatment Landscape
R/R DLBCL: Transplant Eligibility and R-CHOP
Newly Diagnosed DLBCL: Treatment Decision Factors
DLBCL Risk Assessment and Genetic Signatures
Therapy Initiation Prior to Cytogenetic Testing Results
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)